{"id":25450,"date":"2014-06-11T10:37:23","date_gmt":"2014-06-11T14:37:23","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=25450"},"modified":"2014-06-11T10:37:23","modified_gmt":"2014-06-11T14:37:23","slug":"quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450","title":{"rendered":"Quest Diagnostics Inc (NYSE:DGX) Introduces THxID\u00ae-BRAF test"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 06\/11\/2014 (wallstreetpr) \u2013<strong> Quest Diagnostics Inc (NYSE:DGX)<\/strong>, the leading provider of clinical laboratory services has recently announced the launch of a new cancer test service.<\/p>\n<p style=\"text-align: justify;\"><b>bioMerieux THxID\u00ae-BRAF test<\/b><\/p>\n<p style=\"text-align: justify;\">The kit is useful in the detection of the BRAF V600E and V600K mutations in the DNA samples. It is \u2018In Vitro Diagnostic\u2019 device that test FFPE human melanoma tissue. It is based on the THxID\u00ae-BRAF test from bioMerieux.<\/p>\n<p style=\"text-align: justify;\">THxID\u00ae-BRAF test is an FDA approved test. The THxID\u00ae-BRAF test is bundled with the drugs for the treatment of two melanomas. It helps to select the patients suffering from melanoma carrying tumors with BRAF V600E mutation to be treated either with dabrafenib or trametinib.<\/p>\n<p style=\"text-align: justify;\">FDA has approved the use of drugs along with the gene test in May 2013. The drugs are manufactured by GlaxoSmithKline. The drug is used in the treatment of patients suffering from advanced or unresectable melanoma. The THxID-BRAF test kit is manufactured by bioMerieux.<\/p>\n<p style=\"text-align: justify;\"><b>Quest Diagnostics Inc (NYSE:DGX): Leading diagnostics<\/b><\/p>\n<p style=\"text-align: justify;\">Quest Diagnostics Inc (NYSE:DGX) offers the most advanced Dermatopathology testing to improve outcomes that are based on the clinical testing of the patient. It helps the physicians to by guiding them in treatment decisions as well as providing better health facility. Quest is in contact with about half of the US physicians and hospitals. Doctors and patients can now have easy access to the test<\/p>\n<p style=\"text-align: justify;\">\u2018cobas\u00ae 4800 BRAF V600 Mutation test\u2019 by\u00a0\u00a0Quest Diagnostics Inc (NYSE:DGX) helps in the detection of the BRAF V600E mutation and help the \u00a0physicians to select patients to be treated with vemurafenib. Vemurafenib is an oral medicine for patients whose melanoma tumors harbor the mutation.\u00a0 It is an FDA approved test. Quest also offers test for BRAF mutations in melanoma as well as thyroid and colorectal cancers.<\/p>\n<p style=\"text-align: justify;\"><b>Benefits to doctors and patients<\/b><\/p>\n<p style=\"text-align: justify;\">The most reported deaths from skin cancer are caused due to Melanoma. Most of the melanomas are caused due to BRAF gene mutation. It has been estimated that out of 76,100 Americans diagnosed with melanoma; 9,710 will die in 2014.<\/p>\n<p style=\"text-align: justify;\">The hospitals and other physicians can now ask for the test through Quest Diagnostics Inc (NYSE:DGX). The doctors can easily conduct testing through Quest THxID\u00ae-BRAF test. The patients will be benefited the most as doctors can now optimize their treatment after the THxID\u00ae-BRAF test.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 06\/11\/2014 (wallstreetpr) \u2013 Quest Diagnostics Inc (NYSE:DGX), the leading provider of clinical laboratory services has recently announced the launch of a new cancer [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":25454,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[989,5616],"stock_ticker":[],"class_list":["post-25450","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nysedgx","tag-quest-diagnostics-inc-nysedgx","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Quest Diagnostics Inc (NYSE:DGX) Introduces THxID\u00ae-BRAF test - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Quest Diagnostics Inc (NYSE:DGX) Introduces THxID\u00ae-BRAF test - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 06\/11\/2014 (wallstreetpr) \u2013 Quest Diagnostics Inc (NYSE:DGX), the leading provider of clinical laboratory services has recently announced the launch of a new cancer [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-06-11T14:37:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/index9.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"367\" \/>\n\t<meta property=\"og:image:height\" content=\"137\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Brendan Byrne\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Brendan Byrne\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450\"},\"author\":{\"name\":\"Brendan Byrne\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511\"},\"headline\":\"Quest Diagnostics Inc (NYSE:DGX) Introduces THxID\u00ae-BRAF test\",\"datePublished\":\"2014-06-11T14:37:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450\"},\"wordCount\":401,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/index9.jpg\",\"keywords\":[\"NYSE:DGX\",\"Quest Diagnostics Inc (NYSE:DGX)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450\",\"name\":\"Quest Diagnostics Inc (NYSE:DGX) Introduces THxID\u00ae-BRAF test - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/index9.jpg\",\"datePublished\":\"2014-06-11T14:37:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/index9.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/index9.jpg\",\"width\":367,\"height\":137},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Quest Diagnostics Inc (NYSE:DGX) Introduces THxID\u00ae-BRAF test\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511\",\"name\":\"Brendan Byrne\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g\",\"caption\":\"Brendan Byrne\"},\"description\":\"While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email (brendanbyrne@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/u\/0\/116608759701551457422).\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/brendan-byrne\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Quest Diagnostics Inc (NYSE:DGX) Introduces THxID\u00ae-BRAF test - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450","og_locale":"en_US","og_type":"article","og_title":"Quest Diagnostics Inc (NYSE:DGX) Introduces THxID\u00ae-BRAF test - Wall Street PR","og_description":"Boston, MA 06\/11\/2014 (wallstreetpr) \u2013 Quest Diagnostics Inc (NYSE:DGX), the leading provider of clinical laboratory services has recently announced the launch of a new cancer [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-06-11T14:37:23+00:00","og_image":[{"width":367,"height":137,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/index9.jpg","type":"image\/jpeg"}],"author":"Brendan Byrne","twitter_misc":{"Written by":"Brendan Byrne","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450"},"author":{"name":"Brendan Byrne","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511"},"headline":"Quest Diagnostics Inc (NYSE:DGX) Introduces THxID\u00ae-BRAF test","datePublished":"2014-06-11T14:37:23+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450"},"wordCount":401,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/index9.jpg","keywords":["NYSE:DGX","Quest Diagnostics Inc (NYSE:DGX)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450","url":"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450","name":"Quest Diagnostics Inc (NYSE:DGX) Introduces THxID\u00ae-BRAF test - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/index9.jpg","datePublished":"2014-06-11T14:37:23+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/index9.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/index9.jpg","width":367,"height":137},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/quest-diagnostics-inc-nysedgx-introduces-thxid-braf-test-25450#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Quest Diagnostics Inc (NYSE:DGX) Introduces THxID\u00ae-BRAF test"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511","name":"Brendan Byrne","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g","caption":"Brendan Byrne"},"description":"While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email (brendanbyrne@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/u\/0\/116608759701551457422).","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/brendan-byrne"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/25450","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=25450"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/25450\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/25454"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=25450"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=25450"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=25450"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=25450"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}